Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 4,589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

NCT03092232
View directory record Official record
Conditions
Healthy
Interventions
PF-06865571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

NCT06586671
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

NCT02350309
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant-matched placebo., Flurazepam 30 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Crestview Hills, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00778167
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cixutumumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Denver, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 24, 2026, 5:32 PM EDT
Terminated Phase 4 Interventional Results available

Suvorexant in Insomnia Co-morbid With Fibromyalgia

NCT02684136
View directory record Official record
Conditions
Insomnia, Fibromyalgia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT03662334
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
Drug · Device
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 24, 2026, 5:32 PM EDT
Enrolling by invitation Phase 4 Interventional

Precision Medicine Approach for Osteoporosis - Follow Up Study

NCT06264609
View directory record Official record
Conditions
Osteoporosis
Interventions
Alendronate, Teriparatide
Drug
Lead sponsor
Paul F Netzel
Other
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 24, 2026, 5:32 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Crossover Post-herpetic Neuralgia (PHN)

NCT01305538
View directory record Official record
Conditions
Post-Herpetic Neuralgia (PHN)
Interventions
BMS-954561, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Lomita, California • Boulder, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Investigators Conducted a Study to Examine the Impact of Wild Ginseng Extract (WG) on Exercise Performance, Cognitive Function, and Fatigue Recovery Among Twelve Healthy Adult Males

NCT06679725
View directory record Official record
Conditions
Healthy
Interventions
Wild ginseng extract, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University San Antonio
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Cola on Urinary Stone Risk Factors

NCT00289120
View directory record Official record
Conditions
Kidney Stone
Interventions
Cola beverage, Deionized water
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of AG-221 in Healthy Male Subjects

NCT02218346
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG221
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

NCT01875991
View directory record Official record
Conditions
Rheumatoid Arthritis, Plaque Psoriasis
Interventions
Etanercept via Autoinjector A, Etanercept via Autoinjector B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 24, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)

NCT05541679
View directory record Official record
Conditions
Complete Heart Block, High Degree Second Degree Atrioventricular Block, Pacemaker-Induced Cardiomyopathy, Aortic Valve Stenosis
Interventions
Right ventricular septal pacing followed by left bundle branch area pacing, Left bundle branch area pacing followed by right ventricular septal pacing
Device
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Overland Park, Kansas • Ridgewood, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Night Shift Nurses' Health and Reducing Burnout

NCT06829979
View directory record Official record
Conditions
Healthy
Interventions
Access to napping/relaxation room, Blue and green light blocking glasses
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

NCT00876655
View directory record Official record
Conditions
Healthy
Interventions
TR-701 di-sodium phosphate salt, TR-701 free acid phosphate
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 24, 2026, 5:32 PM EDT
Not listed Phase 2 Interventional

Efficacy of Celecoxib 200mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee

NCT00597415
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
celecoxib, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2008 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

NCT03901313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 24, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

NCT01763996
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Febuxostat, Febuxostat placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 24, 2026, 5:32 PM EDT